Massachusetts Financial Services Co. MA Has $37.82 Million Position in IQVIA Holdings Inc. $IQV

Massachusetts Financial Services Co. MA increased its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 16.7% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 199,136 shares of the medical research company’s stock after purchasing an additional 28,447 shares during the period. Massachusetts Financial Services Co. MA owned approximately 0.12% of IQVIA worth $37,824,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in IQV. Asset Dedication LLC lifted its holdings in shares of IQVIA by 224.0% during the second quarter. Asset Dedication LLC now owns 243 shares of the medical research company’s stock worth $38,000 after buying an additional 168 shares during the last quarter. Trust Co. of Toledo NA OH bought a new position in IQVIA during the second quarter worth $39,000. J.Safra Asset Management Corp raised its stake in IQVIA by 208.6% during the 2nd quarter. J.Safra Asset Management Corp now owns 250 shares of the medical research company’s stock valued at $39,000 after purchasing an additional 169 shares during the last quarter. Hemington Wealth Management boosted its holdings in IQVIA by 43.4% in the 3rd quarter. Hemington Wealth Management now owns 261 shares of the medical research company’s stock valued at $49,000 after purchasing an additional 79 shares during the period. Finally, Rothschild Investment LLC increased its holdings in shares of IQVIA by 85.5% during the 2nd quarter. Rothschild Investment LLC now owns 269 shares of the medical research company’s stock worth $42,000 after purchasing an additional 124 shares during the period. Institutional investors and hedge funds own 89.62% of the company’s stock.

Insider Buying and Selling

In other IQVIA news, insider Eric Sherbet sold 4,000 shares of the company’s stock in a transaction dated Wednesday, October 29th. The shares were sold at an average price of $219.70, for a total transaction of $878,800.00. Following the sale, the insider directly owned 27,108 shares of the company’s stock, valued at approximately $5,955,627.60. This represents a 12.86% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 1.60% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on IQV shares. Citigroup increased their target price on shares of IQVIA from $200.00 to $230.00 and gave the company a “neutral” rating in a research note on Wednesday, October 29th. UBS Group raised their price objective on IQVIA from $250.00 to $280.00 and gave the stock a “buy” rating in a research report on Thursday, January 8th. Robert W. Baird set a $258.00 price objective on IQVIA and gave the company an “outperform” rating in a research report on Wednesday, October 29th. HSBC upgraded IQVIA from a “hold” rating to a “buy” rating and upped their target price for the company from $195.00 to $235.00 in a research note on Thursday, October 9th. Finally, Evercore ISI boosted their price target on shares of IQVIA from $220.00 to $240.00 and gave the company an “outperform” rating in a report on Wednesday, October 8th. Two investment analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and five have assigned a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $249.19.

IQVIA Price Performance

Shares of IQV stock opened at $241.28 on Thursday. The stock’s fifty day simple moving average is $228.51 and its 200 day simple moving average is $204.88. IQVIA Holdings Inc. has a one year low of $134.65 and a one year high of $247.04. The firm has a market cap of $41.09 billion, a price-to-earnings ratio of 33.10, a P/E/G ratio of 2.38 and a beta of 1.36. The company has a debt-to-equity ratio of 2.03, a current ratio of 0.70 and a quick ratio of 0.70.

IQVIA (NYSE:IQV) last released its quarterly earnings data on Tuesday, October 28th. The medical research company reported $3.00 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.98 by $0.02. IQVIA had a return on equity of 30.70% and a net margin of 8.07%.The firm had revenue of $4.10 billion during the quarter, compared to analyst estimates of $4.07 billion. During the same period in the prior year, the company posted $2.84 earnings per share. The business’s revenue for the quarter was up 5.2% compared to the same quarter last year. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. On average, analysts expect that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real?world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real?world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.